GlassScriptPhysician profile
Joseph S Mclendon
NPI 1558357731
$9,342.79
in general payments reported to CMS, 2019-2025
43 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,562 · 2020: $792 · 2021: $1,281 · 2022: $1,066 · 2023: $1,568 · 2024: $1,695 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,641.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,275.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $1,154.56 | 2019-2025 | Veozah |
| Novo Nordisk INC | $1,080.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $752.46 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $654.16 | 2019-2025 | |
| Amgen INC. | $563.90 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $507.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.76 | 2019-2025 | Jardiance |
| Dexcom, INC. | $354.35 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $352.23 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Abbott Laboratories | $285.18 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $254.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $206.21 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $192.24 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.60 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mclendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.